Category: Pα+ - Psychedelic Alpha

Our 🎯 Q1 2026 Psychedelic Pipeline Bullseye Charts are now available.

Read more about the article After the Readout: How the Field Is Interpreting Compass’ Phase 3 Psilocybin Data

After the Readout: How the Field Is Interpreting Compass’ Phase 3 Psilocybin Data

Post published:February 20, 2026
Post category:Analysis News Pα+

Read more about the article Compass Provides Fuller Phase 3 Picture, MADRS Curves, on Webcast

Compass Provides Fuller Phase 3 Picture, MADRS Curves, on Webcast

Post published:February 17, 2026
Post category:Analysis News Pα+

Read more about the article BREAKING: Second Positive Phase 3 for Compass’ Psilocybin, Though Modest Magnitude Raises Questions

BREAKING: Second Positive Phase 3 for Compass’ Psilocybin, Though Modest Magnitude Raises Questions

Post published:February 17, 2026
Post category:Analysis News Pα+

Read more about the article Q4’25 Psychedelic Lobbying Update

Q4’25 Psychedelic Lobbying Update

Post published:February 13, 2026
Post category:Analysis News Pα+

Read more about the article Taking the Helm at Helus: A Brief Q&A With New CEO Michael Cola

Taking the Helm at Helus: A Brief Q&A With New CEO Michael Cola

Post published:February 10, 2026
Post category:Interviews Pα+

Read more about the article Pα+ Psychedelic Bulletin #219: Trump Admin. Vetoed Compass Priority Voucher; Ibogaine in Focus; Definium Sued by Former Vendor; Psychedelics Feature in Epstein Files

Pα+ Psychedelic Bulletin #219: Trump Admin. Vetoed Compass Priority Voucher; Ibogaine in Focus; Definium Sued by Former Vendor; Psychedelics Feature in Epstein Files

Post published:February 6, 2026
Post category:Psychedelic Bulletin Pα+

Read more about the article Q3 2025: Oregon Psilocybin Services Update

Q3 2025: Oregon Psilocybin Services Update

Post published:February 2, 2026
Post category:Analysis News Pα+

Read more about the article January 2026 Psychedelic Bill Round-up

January 2026 Psychedelic Bill Round-up

Post published:January 30, 2026
Post category:Analysis Pα+

Read more about the article Pα+ Psychedelic Bulletin #218: FDA’s Farchione Says Psychedelic INDs Are “a Third” of Her Workload; Ipsos/Psychedelic Alpha Poll; Reunion Eyes Single Phase 3 in PPD; America’s 10 Million Microdosers

Pα+ Psychedelic Bulletin #218: FDA’s Farchione Says Psychedelic INDs Are “a Third” of Her Workload; Ipsos/Psychedelic Alpha Poll; Reunion Eyes Single Phase 3 in PPD; America’s 10 Million Microdosers

Post published:January 22, 2026
Post category:Psychedelic Bulletin Pα+

Read more about the article Psychedelic Funding, Public Markets, and M&A in 2025

Psychedelic Funding, Public Markets, and M&A in 2025

Post published:January 20, 2026
Post category:2025 Year in Review Analysis Pα+

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond. Psy Alpha Ltd is a company registered in England and Wales (16989109).

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.